Early Treatment with Hydroxyurea Lessened SCD Severity Among Infants, Study Shows
Jun 27, 2019 07:00 am | Patricia Inacio, PhD
Treatment with hydroxyurea since early infancy, starting at the age of one, is effective and safe at preventing sickle cell disease (SCD) complications, a follow-up study has found. The study “Prospective longitudinal follow-up of children with sickle cell disease treated with hydroxyurea since infancy” was published in journal Pediatric Blood and Cancer. Hydroxyurea is a […]
The post Early Treatment with Hydroxyurea Lessened SCD Severity Among Infants, Study Shows appeared first on Sickle Cell Anemia News. |
Treatment with hydroxyurea since early infancy, starting at the age of one, is effective and safe at preventing sickle cell disease (SCD) complications, a follow-up study has found. The study “Prospective longitudinal follow-up of children with sickle cell disease treated with hydroxyurea since infancy” was published in journal Pediatric Blood and Cancer. Hydroxyurea is a […]
A violinist with vasculitis, two Texas politicians and a pharmaceutical company whose marijuana-derived therapy helps kids with Dravet syndrome were among winners of the 2019 Rare Impact Awards. Officials of the National Organization for Rare Disorders (NORD) presented the awards during a June 22 dinner attended by 550 guests at the NASA Space Center in […]
Imara’s investigational oral inhibitor IMR-687 is well-tolerated, and shows signs of potential for lowering blood biomarkers of sickle cell anemia (SCA), early data from a Phase 2 trial show. The results were presented at the 24th Congress of the European Hematology Association (EHA), held recently in Amsterdam, the Netherlands. “We are encouraged by this interim […]